Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis : report from the transthyretin amyloidosis outcome survey (THAOS) / Arnt V. Kristen, Mathew S. Maurer, Claudio Rapezzi, Rajiv Mundayat, Ole B. Suhr, Thibaud Damy, on behalf of the THAOS investigators
AIM: Cardiac troponins and natriuretic peptides are established for risk stratification in light-chain amyloidosis. Data on cardiac biomarkers in transthyretin amyloidosis (ATTR) are lacking. METHODS AND RESULTS: Patients (n = 1617) with any of the following cardiac biomarkers, BNP (n = 1079), NT-proBNP (n = 550), troponin T (n = 274), and troponin I (n = 108), available at baseline in the Transthyretin Amyloidosis Outcomes Survey (THAOS) were analyzed for differences between genotypes and phenotypes and their association with survival. Median level of BNP was 68.0 pg/mL (IQR 30.5-194.9), NT-proBNP 337.9 pg/mL (IQR 73.0-2584.0), troponin T 0.03 μg/L (IQR 0.01-0.05), and troponin I 0.08 μg/L (IQR 0.04-0.13). NT-proBNP and BNP were higher in wild-type than mutant-type ATTR, troponin T and I did not differ, respectively. Non-Val30Met patients had higher BNP, NT-proBNP and troponin T levels than Val30Met patients, but not troponin I. Late-onset Val30Met was associated with higher levels of troponin I and troponin T compared with early-onset. 115 patients died during a median follow-up of 1.2 years. Mortality increased with increasing quartiles (BNP/NT-proBNP Q1 = 1.7%, Q2 = 5.2%, Q3 = 21.7%, Q4 = 71.3%; troponin T/I Q1 = 6.5%, Q2 = 14.5%, Q3 = 33.9%, Q4 = 45.2%). Three-year overall-survival estimates for BNP/NT-proBNP and troponin T/I quartiles differed significantly (p<0.001). Stepwise risk stratification was achieved by combining NT-proBNP/BNP and troponin T/I. From Cox proportional hazards model, age, modified body mass index, mutation (Val30Met vs. Non-Val30Met) and BNP/NT-proBNP (Q1-Q3 pooled vs. Q4) were identified as independent predictors of survival in patients with mutant-type ATTR. CONCLUSIONS: In this ATTR patient cohort, cardiac biomarkers were abnormal in a substantial percentage of patients irrespective of genotype. Along with age, mBMI, and mutation (Val30Met vs. Non-Val30Met), cardiac biomarkers were associated with surrogates of disease severity with BNP/NT-proBNP identified as an independent predictor of survival in ATTR. TRIAL REGISTRATION: ClinicalTrials.gov NCT00628745..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
PLOS ONE - 12(2017), 4, Artikel-ID e0173086, Seite 1-17 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kristen, Arnt, 1974- [VerfasserIn] |
---|
Links: |
---|
Themen: |
Amyloid Neuropathies, Familial |
---|
Anmerkungen: |
Published: April 6, 2017 Gesehen am 27.06.2018 |
---|
Umfang: |
17 |
---|
doi: |
10.1371/journal.pone.0173086 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
157688578X |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | 157688578X | ||
003 | DE-627 | ||
005 | 20220814175234.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180627s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1371/journal.pone.0173086 |2 doi | |
035 | |a (DE-627)157688578X | ||
035 | |a (DE-576)50688578X | ||
035 | |a (DE-599)BSZ50688578X | ||
035 | |a (OCoLC)1341012801 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Kristen, Arnt |d 1974- |e verfasserin |0 (DE-588)123480965 |0 (DE-627)706314530 |0 (DE-576)293726876 |4 aut | |
245 | 1 | 0 | |a Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis |b report from the transthyretin amyloidosis outcome survey (THAOS) |c Arnt V. Kristen, Mathew S. Maurer, Claudio Rapezzi, Rajiv Mundayat, Ole B. Suhr, Thibaud Damy, on behalf of the THAOS investigators |
264 | 1 | |c 2017 | |
300 | |a 17 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Published: April 6, 2017 | ||
500 | |a Gesehen am 27.06.2018 | ||
520 | |a AIM: Cardiac troponins and natriuretic peptides are established for risk stratification in light-chain amyloidosis. Data on cardiac biomarkers in transthyretin amyloidosis (ATTR) are lacking. METHODS AND RESULTS: Patients (n = 1617) with any of the following cardiac biomarkers, BNP (n = 1079), NT-proBNP (n = 550), troponin T (n = 274), and troponin I (n = 108), available at baseline in the Transthyretin Amyloidosis Outcomes Survey (THAOS) were analyzed for differences between genotypes and phenotypes and their association with survival. Median level of BNP was 68.0 pg/mL (IQR 30.5-194.9), NT-proBNP 337.9 pg/mL (IQR 73.0-2584.0), troponin T 0.03 μg/L (IQR 0.01-0.05), and troponin I 0.08 μg/L (IQR 0.04-0.13). NT-proBNP and BNP were higher in wild-type than mutant-type ATTR, troponin T and I did not differ, respectively. Non-Val30Met patients had higher BNP, NT-proBNP and troponin T levels than Val30Met patients, but not troponin I. Late-onset Val30Met was associated with higher levels of troponin I and troponin T compared with early-onset. 115 patients died during a median follow-up of 1.2 years. Mortality increased with increasing quartiles (BNP/NT-proBNP Q1 = 1.7%, Q2 = 5.2%, Q3 = 21.7%, Q4 = 71.3%; troponin T/I Q1 = 6.5%, Q2 = 14.5%, Q3 = 33.9%, Q4 = 45.2%). Three-year overall-survival estimates for BNP/NT-proBNP and troponin T/I quartiles differed significantly (p<0.001). Stepwise risk stratification was achieved by combining NT-proBNP/BNP and troponin T/I. From Cox proportional hazards model, age, modified body mass index, mutation (Val30Met vs. Non-Val30Met) and BNP/NT-proBNP (Q1-Q3 pooled vs. Q4) were identified as independent predictors of survival in patients with mutant-type ATTR. CONCLUSIONS: In this ATTR patient cohort, cardiac biomarkers were abnormal in a substantial percentage of patients irrespective of genotype. Along with age, mBMI, and mutation (Val30Met vs. Non-Val30Met), cardiac biomarkers were associated with surrogates of disease severity with BNP/NT-proBNP identified as an independent predictor of survival in ATTR. TRIAL REGISTRATION: ClinicalTrials.gov NCT00628745. | ||
650 | 4 | |a Amyloid Neuropathies, Familial | |
650 | 4 | |a Biomarkers | |
650 | 4 | |a Genotype | |
650 | 4 | |a Humans | |
650 | 4 | |a Natriuretic Peptide, Brain | |
650 | 4 | |a Phenotype | |
650 | 4 | |a Surveys and Questionnaires | |
650 | 4 | |a Troponin I | |
650 | 4 | |a Troponin T | |
773 | 0 | 8 | |i Enthalten in |t PLOS ONE |d San Francisco, California, US : PLOS, 2006 |g 12(2017), 4, Artikel-ID e0173086, Seite 1-17 |h Online-Ressource |w (DE-627)523574592 |w (DE-600)2267670-3 |w (DE-576)281331979 |x 1932-6203 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2017 |g number:4 |g elocationid:e0173086 |g pages:1-17 |g extent:17 |
856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0173086 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
856 | 4 | 0 | |u http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0173086 |x Verlag |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_2013 | ||
912 | |a ISIL_DE-16-250 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_34 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_235 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
912 | |a GBV_ILN_2403 | ||
912 | |a GBV_ILN_2403 | ||
912 | |a ISIL_DE-LFER | ||
936 | u | w | |d 12 |j 2017 |e 4 |i e0173086 |h 1-17 |g 17 |
951 | |a AR | ||
952 | |d 12 |j 2017 |e 4 |i e0173086 |h 1-17 |g 17 | ||
980 | |2 2013 |1 01 |x DE-16-250 |b 3013859741 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 27-06-18 | ||
980 | |2 2403 |1 01 |x DE-LFER |b 3017150593 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 10-07-18 | ||
981 | |2 2403 |1 01 |x DE-LFER |r http://dx.doi.org/10.1371/journal.pone.0173086 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2017 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_6 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_17 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1445902249 |a Kristen, Arnt | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416740783 |a Medizinische Universitätsklinik und Poliklinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 |